Aptar Requests U.S. FDA Emergency Use Authorization for N95 Filtering Facepiece Respirator Decontamination with ActivShield™.


Development Strategies for Targeted Delivery of COVID-19 Formulations to the Respiratory Tract

Read description

How to rapidly formulate, select a device and develop a novel concept for nasal and pulmonary drug delivery

Over 300 clinical trials worldwide have been initiated as the race to develop therapies to battle SARS-CoV-2 carries on at a frenetic pace. Both novel and repurposed compounds ranging from antivirals to nucleic acids to bacteriophages for prevention and treatment of COVID-19 are in development. One of the key strategic decisions is where to target drug delivery. As SARS-CoV-2 gains a foothold in the body via the ACE2 receptors located in the nose, nasopharynx and lungs, delivery to the respiratory tract could be a key to beating this virus.

This presentation highlights the pathophysiologic rationale of drug delivery targets in the upper and lower airways. We differentiate key attributes for classes of therapeutic compounds. Building on this foundation allow selection of the appropriate device platform and drive formulation development.

Our goal is to highlight a pathway to rapidly develop a formulation and device combination to that allows clinical trials to start quickly. We provide insight on a formulation and screening processes to establish stability. Acceleration of lead selection to mitigate risk using novel in vitro deposition studies and regional deposition modelling will be discussed.

The need to take a novel concept rapidly to a Phase I or Phase II trial for SARS-CoV-2 is vital. We want to help you get to the clinic faster.

Presented by

Dr. Julie D. Suman PhD, President, Next Breath, an Aptar Pharma Company
Julie holds a B.S. in Pharmacy from Duquesne University (1996) and a Ph.D. in Pharmaceutical Sciences from the University of Maryland, Baltimore (2002). She is a co-editor for Respiratory Drug Delivery Proceedings, an international symposium, and an Affiliate Assistant Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. Julie is a Past-Chair of the AAPS Inhalation Technology Focus Group. She is also a licensed Maryland pharmacist. Julie has published her research in peer-reviewed journals, has presented during podium sessions at international meetings such as the FDA Visiting Professor Lecture Series, and has been an invited speaker at ANVISA in Brazil. Dr. Suman’s doctoral research, which focused on the relationship between in vitro tests for nasal sprays and in vivo deposition, has been recognized for excellence by a research award presented at the International Society for Aerosols in Medicine, 2001.
Dr. Jag Shur CEO, Nanopharm, an Aptar Pharma Company
Jag’s main area of research is investigation of the bioequivalence of orally inhaled and nasal drug products (OINDPs). The key theme of his research has been the development and application of novel tools to understand and quantify the microstructure of OINDPs. He began his career with Profile Drug Delivery (now Philips Respironics) where he developed liquid dose drug delivery systems for cystic fibrosis patients, and later went on to work for GlaxoSmithKline. Jag holds a BSc (Hons) in Chemistry and completed his PhD, entitled ‘Formulated Muco-Regulatory Agents in the Airways of Patients with Cystic Fibrosis’, at Portsmouth School of Pharmacy. Following this, he was a post-doctoral fellow at the London School of Pharmacy, investigating the fabrication of microparticles for vaccine delivery using supercritical fluid technology.
Please register to view the webinar :Already registered ?
Mandatory fields

*The information marked with (*) is essential to process your request. Failure to provide such information may prevent us from fulfilling your request. Your personal data will be used only for Aptar to process an information request and/or job application and will be made accessible to Aptar and to any third party for exclusively technical and logistical reasons, notably to our services located outside the European Union, being specified that, in the event that the recipient country does not ensure a level of data protection equivalent to that of the European Union, Aptar undertakes to take all relevant guarantees, either on the basis of an adequacy decision or, in the absence of such a decision, on the basis of appropriate safeguards, a copy of which may be requested from the contact email below. Your personal data will only be kept for a period that does not exceed the applicable statutory limitation periods. Any contact data will be made accessible to Aptar and to third parties that provide technical and logistical support to Aptar for the purpose of your contact request.

If any after communication upon receipt of a valid identity document, you have the right to access, modify, rectify, limit, delete and ask, if any, the portability of your personal data as well as a right of opposition, if necessary subject to legitimate and imperative reasons, to the processing of such data. You may also define guidelines for the use of your personal data in the event of death.

If you wish to exercise this option or if you have any questions regarding our General Terms and Conditions of Use, Privacy and Cookies Policy, please contact Aptar at: informationgovernance@aptar.com

You also have the right to lodge a complaint at the relevant data protection authority in your own jurisdiction.

June 15, 2020 3PM London / 10AM New York 60 min
Watch now
Presented by
Dr. Julie D. Suman PhD, President, Next Breath, an Aptar Pharma Company
Dr. Jag Shur CEO, Nanopharm, an Aptar Pharma Company
Read more
Key Learning Objectives
  • Describe rationale to target SARS-CoV-2 therapies to the nose and lung
  • Understand formulation and device considerations for respiratory drug delivery
  • Apply physiologic modelling for targeted drug delivery
  • Outline a development strategy to accelerate lead candidate selection for early clinical trials
Do you have questions about this webinar ?
Contact us